Oramed Pharmaceuticals/$ORMP
1D1W1MYTD1Y5YMAX
Capital at risk
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
- Ticker
- $ORMP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4
- Headquarters
- New York, United States
- Website
- oramed.com
ORMP Metrics
BasicAdvanced
$194M
1.13
$4.15
1.16
$0.25
5.35%
Price and volume
Market cap
$194M
Beta
1.16
52-week high
$5.47
52-week low
$2.09
Average daily volume
204K
Dividend rate
$0.25
Financial strength
Current ratio
4.977
Quick ratio
4.846
Long term debt to equity
0.002
Total debt to equity
0.002
Dividend payout ratio (TTM)
5.97%
Profitability
EBITDA (TTM)
-14.402
Effective tax rate (TTM)
20.62%
Management effectiveness
Return on assets (TTM)
-3.42%
Return on equity (TTM)
74.24%
Valuation
Price to earnings (TTM)
1.126
Price to book
0.61
Price to tangible book (TTM)
0.61
Price to free cash flow (TTM)
-36.816
Free cash flow yield (TTM)
-2.72%
Free cash flow per share (TTM)
-0.127
Dividend yield (TTM)
5.35%
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-788.02%
3-year earnings per share growth (CAGR)
101.29%
What the Analysts think about ORMP
Analyst ratings (Buy, Hold, Sell) for Oramed Pharmaceuticals stock.
Analyst projections of the future price of Oramed Pharmaceuticals stock.
ORMP Financial Performance
Revenues and expenses
ORMP Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.